Puneet Souda
Stock Analyst at Leerink Partners
(1.96)
# 3,130
Out of 5,148 analysts
220
Total ratings
47.49%
Success rate
-0.97%
Average return
Main Sectors:
Stocks Rated by Puneet Souda
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GH Guardant Health | Maintains: Outperform | $170 → $180 | $92.23 | +95.16% | 8 | Feb 20, 2026 | |
| TMO Thermo Fisher Scientific | Maintains: Outperform | $545 → $580 | $508.58 | +14.04% | 20 | Oct 22, 2025 | |
| HOLX Hologic | Maintains: Market Perform | $70 → $78 | $75.45 | +3.38% | 8 | Oct 21, 2025 | |
| CYRX Cryoport | Upgrades: Outperform | $16 | $8.21 | +94.88% | 7 | Aug 6, 2025 | |
| MASS 908 Devices | Upgrades: Outperform | $12 | $6.61 | +81.54% | 7 | Aug 5, 2025 | |
| QTRX Quanterix | Downgrades: Market Perform | $12 → $8 | $6.33 | +26.38% | 12 | Apr 30, 2025 | |
| NEO NeoGenomics | Downgrades: Market Perform | $25 → $9 | $9.50 | -5.26% | 10 | Apr 30, 2025 | |
| MYGN Myriad Genetics | Downgrades: Market Perform | $30 → $21 | $5.01 | +319.16% | 7 | Dec 9, 2024 | |
| VCYT Veracyte | Maintains: Outperform | $35 → $40 | $36.01 | +11.08% | 14 | Oct 17, 2024 | |
| NTRA Natera | Maintains: Outperform | $140 → $150 | $200.17 | -25.06% | 7 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $325 → $375 | $307.23 | +22.06% | 15 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $35 | $27.99 | +25.04% | 11 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $170 → $145 | $118.17 | +22.70% | 19 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $300 | $206.00 | +45.63% | 1 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $249 → $250 | $132.89 | +88.13% | 19 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $110 | $57.82 | +90.25% | 6 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $75 | $103.35 | -27.43% | 16 | Jan 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $230 → $200 | $124.97 | +60.04% | 7 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $3.82 | +371.20% | 6 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $6 | $1.76 | +240.91% | 1 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $45 → $30 | $45.89 | -34.63% | 6 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $87 | $39.81 | +118.54% | 13 | May 5, 2022 |
Guardant Health
Feb 20, 2026
Maintains: Outperform
Price Target: $170 → $180
Current: $92.23
Upside: +95.16%
Thermo Fisher Scientific
Oct 22, 2025
Maintains: Outperform
Price Target: $545 → $580
Current: $508.58
Upside: +14.04%
Hologic
Oct 21, 2025
Maintains: Market Perform
Price Target: $70 → $78
Current: $75.45
Upside: +3.38%
Cryoport
Aug 6, 2025
Upgrades: Outperform
Price Target: $16
Current: $8.21
Upside: +94.88%
908 Devices
Aug 5, 2025
Upgrades: Outperform
Price Target: $12
Current: $6.61
Upside: +81.54%
Quanterix
Apr 30, 2025
Downgrades: Market Perform
Price Target: $12 → $8
Current: $6.33
Upside: +26.38%
NeoGenomics
Apr 30, 2025
Downgrades: Market Perform
Price Target: $25 → $9
Current: $9.50
Upside: -5.26%
Myriad Genetics
Dec 9, 2024
Downgrades: Market Perform
Price Target: $30 → $21
Current: $5.01
Upside: +319.16%
Veracyte
Oct 17, 2024
Maintains: Outperform
Price Target: $35 → $40
Current: $36.01
Upside: +11.08%
Natera
Oct 17, 2024
Maintains: Outperform
Price Target: $140 → $150
Current: $200.17
Upside: -25.06%
Aug 1, 2024
Upgrades: Outperform
Price Target: $325 → $375
Current: $307.23
Upside: +22.06%
Jun 5, 2023
Maintains: Outperform
Price Target: $50 → $35
Current: $27.99
Upside: +25.04%
May 24, 2023
Maintains: Outperform
Price Target: $170 → $145
Current: $118.17
Upside: +22.70%
May 1, 2023
Initiates: Outperform
Price Target: $300
Current: $206.00
Upside: +45.63%
Feb 8, 2023
Maintains: Outperform
Price Target: $249 → $250
Current: $132.89
Upside: +88.13%
Feb 3, 2023
Maintains: Outperform
Price Target: $125 → $110
Current: $57.82
Upside: +90.25%
Jan 12, 2023
Maintains: Outperform
Price Target: $70 → $75
Current: $103.35
Upside: -27.43%
Jan 6, 2023
Maintains: Outperform
Price Target: $230 → $200
Current: $124.97
Upside: +60.04%
Jan 6, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $3.82
Upside: +371.20%
Nov 29, 2022
Initiates: Outperform
Price Target: $6
Current: $1.76
Upside: +240.91%
Nov 21, 2022
Maintains: Market Perform
Price Target: $45 → $30
Current: $45.89
Upside: -34.63%
May 5, 2022
Maintains: Outperform
Price Target: $85 → $87
Current: $39.81
Upside: +118.54%